Inhibrx Biosciences (INBX) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Inhibrx Biosciences (INBX) is Neutral.

The composite score behind that read is -0.06, weighing +0.71 of bullish evidence against -0.28 bearish.

Inhibrx Biosciences last closed at $95.01, +2.43% on the session.

Against the IVW growth benchmark the position is +1.63% over the forecast window.

The read is built from 15 underlying insights — 1 bullish and 14 bearish.

Agreement across those insights is 93%.

20 graded predictions for INBX so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Inhibrx Biosciences in the 100th percentile on return on equity, where 100 is best.

Inhibrx Biosciences is classified under Health Care / Biotechnology, with a market capitalisation of $1.37B.

StockMap tracks Inhibrx Biosciences as the 117th largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite Inhibrx Biosciences ranks 160th of 381 in the group, against a group median of -0.08.